CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...
NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
Low Vision Specialists of Maryland & Virginia marks five decades of helping patients with macular degeneration and complex ...
Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...
The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic ...
One of the best ways to improve eyesight is consuming enough vitamin A which can be found in foods like carrots, sweet potatoes, and spinach. You can also protect your eyesight from further damage by ...
Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...
Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.
Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results